RO

Dl Petru CRACIUN, membru in Consiliul de Administratie, a facut o scurta prezentare a rezultatelor financiare ale Farmaceutica REMEDIA S.A. la trimestrul III 2019.

Dl Adrian PANAITE, Profit si Vlad DOBREA / Ziarul Bursa au solicitat detalierea obiectivelor convocatorului AGEA din 4/5.12.2019, iar dl Petru CRACIUN explica ca in conditiile in care in filozofia de grup de talie medie, integrat retail-distributie, care a functionat bine in ultimii 10-15 ani, cresterea veniturilor poate fi obtinuta doar cu o crestere nerezonabila de costuri, poate fi oportun ca Farmaceutica REMEDIA S.A. sa exploreze si alte optiuni. Exista un interes pe piata, de mai multa vreme, pentru farmaciile REMEDIA, care pana acum nu s-a concretizat; in conditiile in care pe piata au intrat deja 2 (doi) jucatori mari importanti (Penta/Dr. Max si Phoenix) si exista si alte entitati interesate, Consiliul de Administratie poate discuta cu mai multi potentiali cumparatori si poate alege pe cel care va oferi conditiile cele mai bune pt o parte semnificativa sau totalul acestora.

La intrebarea cum apreciaza Farmaceutica REMEDIA S.A. trendul costurilor cu chiriile in orasele mari, dl Petru CRACIUN a subliniat faptul ca atat costurile cu chiriile, cat si cele cu salariile, devin din ce in ce mai greu de gestionat in contextul actual, in special in orase mari; trendul de consolidare a pietei de catre jucatorii mari poate crea impresia din partea locatorilor ca exista posibilitatea de a negocia chiriile la preturi ridicate.

Dl Petru CRACIUN precizeaza ca Farmaceutica REMEDIA S.A.  este inca in faza de identificare a unui potential cumparator si nu are o oferta si termeni concreti la aceasta etapa de la nici un investitor.

In ce priveste intrebarea daca s-a considerat necesitatea aprobarii de catre Consiliul Concurentei a eventualei tranzactii, Dl Petru CRACIUN explica ca aceasta va fi considerata in etapa ulterioara in care, daca vor exista elemente concrete ale tranzactiei si aprobarea Consiliul Concurentei este necesara, va fi supusa procesului de obtinere.

In ce priveste intrebarea daca s-a considerat necesitatea aprobarii de catre Consiliul Concurentei a eventualei tranzactii, Dl Petru CRACIUN explica ca aceasta va fi considerata in etapa ulterioara in care, daca vor exista elemente concrete ale tranzactiei si aprobarea Consiliul Concurentei este necesara, va fi supusa procesului de obtinere.

EN

Mr. Petru CRACIUN, the member of the Board of Administrators, gave a brief presentation of the financial results of Farmaceutica REMEDIA S.A. at the third quarter of 2019.

Mr. Adrian PANAITE, Profit and Vlad DOBREA, Bursa asked to detail the objectives of the EGMS convener from 4 / 5.12.2019, and Mr. Petru CRACIUN explains that in the conditions in which the philosophy of medium-sized group, integrated retail-distribution, which worked well in the last 10-15 years, revenue growth can only be achieved with unreasonable cost growth, it may be appropriate for Farmaceutica REMEDIA SA to explore other options. There is a long-standing interest in the market for REMEDIA pharmacies, which has not yet materialized; given that 2 (two) major players (Penta / Dr. Max and Phoenix) have already entered the market and there are other interested entities, the Board of Administrators can discuss with several potential buyers and can choose the one that will offer it the best conditions for a significant part or all of them.

To the question how appreciates Farmaceutica REMEDIA S.A. the trend of costs with rents in big cities, Mr. Petru CRACIUN pointed out that both costs with rents and salaries, are becoming more difficult to be managed under the current context, especially in big cities; the tendency of consolidation of the market by the big players can create the impression from the renters that there is the possibility to negotiate the rents at high prices.

Mr. Petru CRACIUN specifies that Farmaceutica REMEDIA S.A. is still in the phase of identifying a potential buyer and does not have a concrete offer and terms at this stage from any investor.

Regarding the question if it was considered the need for the Competition Council’s approval of the eventual transaction, Mr. Petru CRACIUN explains that this will be considered in the next stage where, if there are concrete elements of the transaction and the approval of the Competition Council will be subject to the process to obtain.

No Comment

Comments are closed.